DDInter1008 DDInter462
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Ketoconazole {u} (Compound) upregulates {v} (Gene) ABHD4
ABHD4 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ketoconazole {u} (Compound) downregulates {v} (Gene) SLC35F2
SLC35F2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Ketoconazole {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Ketoconazole {u} (Compound) upregulates {v} (Gene) ABHD4
ABHD4 {u} (Gene) is regulated by {v} (Gene) EAPP
EAPP {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ketoconazole {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) regulates {v} (Gene) NARFL
NARFL {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ketoconazole {u} (Compound) downregulates {v} (Gene) SLC35F2
SLC35F2 {u} (Gene) is regulated by {v} (Gene) RAF1
RAF1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Ketoconazole (Compound) upregulates ABHD4 (Gene) and ABHD4 (Gene) is upregulated by Dabrafenib (Compound)
Ketoconazole (Compound) downregulates SLC35F2 (Gene) and SLC35F2 (Gene) is downregulated by Dabrafenib (Compound)
Ketoconazole (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Ketoconazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Ketoconazole (Compound) upregulates ABHD4 (Gene) and ABHD4 (Gene) is regulated by EAPP (Gene) and EAPP (Gene) is upregulated by Dabrafenib (Compound)
Ketoconazole (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) regulates NARFL (Gene) and NARFL (Gene) is upregulated by Dabrafenib (Compound)
Ketoconazole (Compound) downregulates SLC35F2 (Gene) and SLC35F2 (Gene) is regulated by RAF1 (Gene) and RAF1 (Gene) is bound by Dabrafenib (Compound)